Potential of ESBL-producing Escherichia coli selection in bovine feces after intramammary administration of first generation cephalosporins using in vitro experiments
Speksnijder, David C; Hopman, Nonke E M; Kusters, Nina E; Timmerman, Arjen; Swinkels, Jantijn M; Penterman, Pleun A A; Krömker, Volker; Bradley, Andrew J; Botteldoorn, Nadine; Gehring, Ronette; Zomer, Aldert L
(2022) Scientific Reports, volume 12, issue 1, pp. 1 - 10
(Article)
Abstract
Selection and spread of Extended Spectrum Beta-Lactamase (ESBL) -producing Enterobacteriaceae within animal production systems and potential spillover to humans is a major concern. Intramammary treatment of dairy cows with first-generation cephalosporins is a common practice and potentially selects for ESBL-producing Enterobacteriaceae, although it is unknown whether this really occurs in
... read more
the bovine fecal environment. We aimed to study the potential effects of intramammary application of cephapirin (CP) and cefalonium (CL) to select for ESBL-producing Escherichia coli in the intestinal content of treated dairy cows and in manure slurry, using in vitro competition experiments with ESBL and non-ESBL E. coli isolates. No selection of ESBL-producing E. coli was observed at or below concentrations of 0.8 µg/ml and 4.0 µg/ml in bovine feces for CP and CL, respectively, and at or below 8.0 µg/ml and 4.0 µg/ml, respectively, in manure slurry. We calculated that the maximum concentration of CP and CL after intramammary treatment with commercial products will not exceed 0.29 µg/ml in feces and 0.03 µg/ml in manure slurry. Therefore, the results of this study did not find evidence supporting the selection of ESBL-producing E. coli in bovine feces or in manure slurry after intramammary use of commercial CP or CL-containing products.
show less
Download/Full Text
ISSN: 2045-2322
Publisher: NLM (Medline)
Note: Funding Information: This study was funded by the Global Ruminant Business Unit, MSD Animal Health represented by JS and PP. DS, NH, AT, NK and AZ were funded out of this budget to perform the study. The funder did not have any influence in the design of the study, the analyses and interpretation of the study results and in writing the manuscript. VK, AB, NB and RG were not paid for their contribution in this study. All authors declare no conflicts of interests. Funding Information: This study was funded by the Global Ruminant Business Unit, MSD Animal Health represented by JS and PP. DS, NH, AT, NK and AZ were funded out of this budget to perform the study and/or write the manuscript. The funder did however not have any influence in the design of the study, the analyses and interpretation of the study results and in writing the manuscript. VK, AB, NB and RG were not paid for their contribution in this study except for logistical costs related to sampling and shipment of samples. All authors declare no conflicts of interests. The funder did review the paper but did not influence the initial conclusions of the principal investigators. We as principal investigators declare that we guarded our scientific integrity in conducting this study and in writing the manuscript. Publisher Copyright: © 2022, Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
(Peer reviewed)
See more statistics about this item